Continue Reading Below
After the company reported compelling results from a late-stage trial for a combination therapy for use in cystic fibrosis patients, shares in Vertex Pharmaceuticals (NASDAQ: VRTX) skyrocketed 21.1% in March,according toS&P Global Market Intelligence.
Cystic fibrosis is a serious, life-shortening disease affecting about 75,000 people globally, and while treatment options are limited, Vertex Pharmaceuticals is changing that.
IMAGE SOURCE: GETTY IMAGES.
The company already markets Orkambi and Kalydeco, and those drugs can help about one-third of patients. Also,it's studying additional therapies that may eventually help the remaining two-thirds of cystic fibrosis patients.
Continue Reading Below
For example, management recently reported phase 3 results from two studies evaluating a combination of Kalydeco and a new drug, tezacaftor.
In one trial, patients with two copies of the F508del mutation who were given Vertex Pharmaceuticals' combination drug saw statistically significant improvements in lung function, compared to placebo. The combination therapy similarly met its primary endpoint in a second trial involving patients with a mutation that results in residual CFTR (a protein that regulates important functions in the lungs and other organs) function and one copy of the F508del mutation.
Overall, the results were good enough for management to say it's planning on filing for approval with the U.S. Food and Drug Administration in the third quarter, and that timeline suggests this combination therapy could be available as soon as 2018.
If regulators give Vertex's combination therapy an OK, then the company will see a significant expansion in the number of patients its therapies address. Currently, Vertex Pharmaceuticals' Kalydeco and Orkambi benefit about 29,000 patients; if approved, this new approach could help 23,000 patients.
A big expansion of its addressable market would unquestionably be good news for the company's investors. Last year, Vertex Pharmaceuticals reported revenue of about $1.7 billion, yet it still lost more than $100 million because of its spending on marketing and research. If an approval allows this company to move into the black, its shares could soar higher still.
10 stocks we like better than Vertex Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Todd Campbell has no position in any stocks mentioned.His clients may have positions in the companies mentioned.The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.